Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer

BACKGROUND: Tamoxifen is the cornerstone of adjuvant therapy for hormone receptor-positive breast cancer. Despite its efficacy, limited drug sensitivity and endocrine resistance remain the important clinical challenges. The main objective of this study was to investigate fatostatin, which was found...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ying, Zhang, Ning, Zhang, Hanwen, Wang, Lijuan, Duan, Yi, Wang, Xiaolong, Chen, Tong, Liang, Yiran, Li, Yaming, Song, Xiaojin, Li, Chen, Han, Dianwen, Chen, Bing, Zhao, Wenjing, Yang, Qifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457819/
https://www.ncbi.nlm.nih.gov/pubmed/32921987
http://dx.doi.org/10.2147/DDDT.S253876

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457819/
https://www.ncbi.nlm.nih.gov/pubmed/32921987
http://dx.doi.org/10.2147/DDDT.S253876

Ejemplares similares